Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial

Dose Escalation Study ◽

Cell Antigen ◽

Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-10-2955 ◽

2010 ◽

Vol 17 (4) ◽

pp. 880-887 ◽

Cited By ~ 31

Author(s):

Dana Rathkopf ◽

Glenn Liu ◽

Michael A. Carducci ◽

Mario A. Eisenberger ◽

Aseem Anand ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Dose Escalation ◽

The Novel ◽

Dose Escalation Study ◽

Open-label, phase I, dose escalation study to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E (GEN0101) in castration-resistant prostate cancer patients

European Urology Supplements ◽

10.1016/s1569-9056(19)30876-0 ◽

2019 ◽

Vol 18 (1) ◽

pp. e1220

Author(s):

K. Fujita ◽

Y. Nakai ◽

D. Kato ◽

A. Kawashima ◽

T. Ujike ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Cancer Patients ◽

Dose Escalation ◽

Open Label ◽

Dose Escalation Study ◽

Safety And Efficacy ◽

Castration Resistant ◽

Open Label Phase

Phase I dose-escalation study of AGS-1C4D4, an anti-PSCA human antibody in castration-resistant prostate cancer (CRPC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.4669 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 4669-4669

Author(s):

M. A. Carducci ◽

M. A. Eisenberger ◽

S. R. Denmeade ◽

S. F. Slovin ◽

A. Jakobovits ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Dose Escalation ◽

Human Antibody ◽

Dose Escalation Study ◽

Abstract CT122: Phase I dose-escalation study of prostate-specific membrane antigen (PSMA)-targeted alpha emitter225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC)

10.1158/1538-7445.am2020-ct122 ◽

2020 ◽

Author(s):

Scott T. Tagawa ◽

Joseph Osborne ◽

Charlene Thomas ◽

Escarleth Fernandez ◽

Muhammad J. Niaz ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Dose Escalation ◽

Prostate Specific Membrane Antigen ◽

Dose Escalation Study ◽

Castration Resistant ◽

Specific Membrane

Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)

Annals of Oncology ◽

10.1093/annonc/mdz248.006 ◽

2019 ◽

Vol 30 ◽

pp. v329-v330 ◽

Cited By ~ 1

Author(s):

S.T. Tagawa ◽

J.R. Osborne ◽

A. Hackett ◽

M.J. Niaz ◽

V. Cooley ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Dose Escalation ◽

Dose Escalation Study ◽

Preliminary Results ◽

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

Annals of Oncology ◽

10.1016/j.annonc.2020.01.074 ◽

2020 ◽

Vol 31 (5) ◽

pp. 619-625 ◽

Cited By ~ 3

Author(s):

M.P. Kolinsky ◽

P. Rescigno ◽

D. Bianchini ◽

Z. Zafeiriou ◽

N. Mehra ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Dose Escalation ◽

Akt Inhibitor ◽

Dose Escalation Study ◽

Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)

Annals of Oncology ◽

10.1093/annonc/mdy284.008 ◽

2018 ◽

Vol 29 ◽

pp. viii274 ◽

Cited By ~ 1

Author(s):

S.T. Tagawa ◽

S. Vallabhajosula ◽

Y. Jhanwar ◽

A. Hackett ◽

C. Oromendia ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Dose Escalation ◽

Dose Escalation Study ◽

Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer

British Journal of Cancer ◽

10.1038/sj.bjc.6605798 ◽

2010 ◽

Vol 103 (4) ◽

pp. 462-468 ◽

Cited By ~ 30

Author(s):

N M Corcoran ◽

C M Hovens ◽

M Michael ◽

M A Rosenthal ◽

A J Costello

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Dose Escalation ◽

Sodium Selenate ◽

Open Label ◽

Dose Escalation Study ◽

Castration Resistant ◽

Open Label Phase

599P A phase I dose-escalation study of LAE001/prednisone plus afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1112 ◽

2021 ◽

Vol 32 ◽

pp. S644-S645

Author(s):

A. Bessudo ◽

X. Wang ◽

J.F. Strauss ◽

D.E. Slater ◽

C. Pieczonka ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Dose Escalation ◽

Standard Of Care ◽

Dose Escalation Study ◽

597P A phase I dose-escalation study of LAE001 in patients with metastatic castration-resistant prostate cancer (mCRPC)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1110 ◽

2021 ◽

Vol 32 ◽

pp. S643

Author(s):

D. Ye ◽

R. Liu ◽

H. Luo ◽

W. Han ◽

X. Lu ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Dose Escalation ◽

Dose Escalation Study ◽